15.83 USD
-0.41 (-2.52%)
ADPT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of ADPT have multiple concerns. ADPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ADPT had negative earnings in the past year.
ADPT had a negative operating cash flow in the past year.
ADPT had negative earnings in each of the past 5 years.
In the past 5 years ADPT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -16.29%, ADPT perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
ADPT has a Return On Equity of -39.09%. This is in the lower half of the industry: ADPT underperforms 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.29% | ||
| ROE | -39.09% | ||
| ROIC | N/A |
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 71.84%, ADPT belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
In the last couple of years the Gross Margin of ADPT has declined.
ADPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
2. Health
2.1 Basic Checks
ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADPT has more shares outstanding
Compared to 5 years ago, ADPT has more shares outstanding
ADPT has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.82 indicates that ADPT is not a great score, but indicates only limited risk for bankruptcy at the moment.
ADPT has a Altman-Z score of 1.82. This is comparable to the rest of the industry: ADPT outperforms 50.88% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that ADPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, ADPT is doing worse than 70.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.82 |
ROIC/WACCN/A
WACC10.83%
2.3 Liquidity
ADPT has a Current Ratio of 3.38. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.38, ADPT is in line with its industry, outperforming 59.65% of the companies in the same industry.
A Quick Ratio of 3.26 indicates that ADPT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.26, ADPT is doing good in the industry, outperforming 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.26 |
3. Growth
3.1 Past
ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.45%, which is quite impressive.
ADPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.57%.
The Revenue has been growing by 16.03% on average over the past years. This is quite good.
EPS 1Y (TTM)53.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
Revenue 1Y (TTM)42.57%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%102.38%
3.2 Future
Based on estimates for the next years, ADPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.75% on average per year.
The Revenue is expected to grow by 21.76% on average over the next years. This is a very strong growth
EPS Next Y54.26%
EPS Next 2Y20.91%
EPS Next 3Y18.48%
EPS Next 5Y12.75%
Revenue Next Year48.93%
Revenue Next 2Y22.75%
Revenue Next 3Y22.42%
Revenue Next 5Y21.76%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ADPT's earnings are expected to grow with 18.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.91%
EPS Next 3Y18.48%
5. Dividend
5.1 Amount
ADPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ADPT (1/2/2026, 2:12:09 PM)
15.83
-0.41 (-2.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.08%
Inst Owner Change-2.3%
Ins Owners2.48%
Ins Owner Change-4.39%
Market Cap2.42B
Revenue(TTM)252.75M
Net Income(TTM)-79.92M
Analysts84.29
Price Target20.25 (27.92%)
Short Float %6.54%
Short Ratio4.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)85.21%
Min EPS beat(2)30.19%
Max EPS beat(2)140.22%
EPS beat(4)4
Avg EPS beat(4)53.85%
Min EPS beat(4)12%
Max EPS beat(4)140.22%
EPS beat(8)8
Avg EPS beat(8)33.22%
EPS beat(12)10
Avg EPS beat(12)23.99%
EPS beat(16)14
Avg EPS beat(16)20.79%
Revenue beat(2)2
Avg Revenue beat(2)29.69%
Min Revenue beat(2)16.85%
Max Revenue beat(2)42.52%
Revenue beat(4)4
Avg Revenue beat(4)20.23%
Min Revenue beat(4)1.07%
Max Revenue beat(4)42.52%
Revenue beat(8)7
Avg Revenue beat(8)12.77%
Revenue beat(12)9
Avg Revenue beat(12)7.89%
Revenue beat(16)12
Avg Revenue beat(16)5.97%
PT rev (1m)3.73%
PT rev (3m)41.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.58%
EPS NY rev (1m)27.99%
EPS NY rev (3m)32.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.1%
Revenue NY rev (1m)10.54%
Revenue NY rev (3m)13.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 11.82 | ||
| P/tB | 29.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.66
BVpS1.34
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.29% | ||
| ROE | -39.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.84% | ||
| FCFM | N/A |
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.3% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.26 | ||
| Altman-Z | 1.82 |
F-Score4
WACC10.83%
ROIC/WACCN/A
Cap/Depr(3y)48.38%
Cap/Depr(5y)161.41%
Cap/Sales(3y)5.71%
Cap/Sales(5y)15.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
EPS Next Y54.26%
EPS Next 2Y20.91%
EPS Next 3Y18.48%
EPS Next 5Y12.75%
Revenue 1Y (TTM)42.57%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%102.38%
Revenue Next Year48.93%
Revenue Next 2Y22.75%
Revenue Next 3Y22.42%
Revenue Next 5Y21.76%
EBIT growth 1Y53.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.04%
EBIT Next 3Y28.09%
EBIT Next 5Y17.61%
FCF growth 1Y63.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.33%
OCF growth 3YN/A
OCF growth 5YN/A
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you provide the ChartMill fundamental rating for ADAPTIVE BIOTECHNOLOGIES?
ChartMill assigns a fundamental rating of 2 / 10 to ADPT.
What is the valuation status for ADPT stock?
ChartMill assigns a valuation rating of 0 / 10 to ADAPTIVE BIOTECHNOLOGIES (ADPT). This can be considered as Overvalued.
Can you provide the profitability details for ADAPTIVE BIOTECHNOLOGIES?
ADAPTIVE BIOTECHNOLOGIES (ADPT) has a profitability rating of 1 / 10.
How financially healthy is ADAPTIVE BIOTECHNOLOGIES?
The financial health rating of ADAPTIVE BIOTECHNOLOGIES (ADPT) is 3 / 10.